2JUN

Bundibugyo's 14% death rate is an undercount

3 min read

09:17UTC

Bundibugyo's confirmed case-fatality ratio sits near 14%, between seasonal flu's 0.1% and classic Zaire Ebola's 50%. With 906 suspected cases untested, that figure measures only the patients who lived long enough to reach a laboratory.

← Back to Ebola money arrives, the cure does not Jump to analysis ↓

ScienceAssessed

Key takeaway

Bundibugyo's recorded 14% death rate counts only tested survivors, so the true lethality is almost certainly higher.

WHO bulletin DON605 recorded 18 deaths among 134 laboratory-confirmed Bundibugyo cases on 29 May, a confirmed case-fatality ratio near 14%⁠¹. The case-fatality ratio measures the share of confirmed patients who die. At 14%, Bundibugyo ebolavirus sits well below the roughly 50% seen in classic Zaire Ebola and far above seasonal influenza's 0.1%.

That 14% is almost certainly an undercount. The same bulletin recorded a suspected-to-confirmed ratio of 6.8 to one for the outbreak's caseload, the breakdown detailed in this briefing's headline figures. For every patient the laboratory confirms, nearly seven more are suspected but untested, and many are dying before a swab reaches them.

The recorded lethality is therefore the lethality among those who lived long enough to be tested. People who die quickly, before any sample is taken, never enter the case-fatality calculation at all. Ever since the global emergency was declared on 17 May, the response has chased a transmission curve that detection and testing both lag, so the laboratory-confirmed death rate is a floor on the true figure, not an estimate of it.

Deep Analysis

In plain English

The case-fatality ratio (CFR) is the proportion of people who die out of those known to be infected. For this outbreak, WHO reports a CFR of approximately 14% among laboratory-confirmed cases. But that figure has two important caveats. First, a 6.8:1 ratio of suspected to confirmed cases means that for every person with a laboratory test, nearly seven others are counted only as suspected cases. Many of these suspected patients may be infected but never got tested, either because they died before a swab could be taken, or because they live too far from a functioning laboratory. Some deaths in the suspected group do not count toward the confirmed-case CFR. Second, scientists measure CFR differently depending on which denominator they use. Using confirmed cases gives 14%; using all suspected cases gives roughly 24%. The true figure is somewhere between those two numbers, and public health agencies choose their approach based on what is measurable, not necessarily what is most accurate.

Deep Analysis

Root Causes

The 6.8:1 suspected-to-confirmed ratio has two structural drivers. The first is laboratory throughput: the INRB laboratory in Kinshasa processes samples from Ituri across a cold-chain transport chain, and turn-around times for community samples are two to four days at best. Patients with severe acute haemorrhagic fever often die within four to seven days of symptom onset, meaning a meaningful proportion die before their swab result returns.

The second driver is healthcare-seeking behaviour shaped by community distrust: patients who do not come to treatment centres, or who come only in the terminal phase of illness, are less likely to have a swab taken and processed before death. This connects directly to the treatment-centre arson and M23 access constraints documented in event index 5: a damaged community interface reduces laboratory confirmation rates and therefore inflates the suspected-to-confirmed gap.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The 2007 Bundibugyo, Uganda outbreak produced 131 cases and 39 deaths, a confirmed CFR of approximately 30%. Subsequent phylogenetic and community-survey work by researchers at the Uganda Virus Research Institute found that seroprevalence in the affected community was substantially higher than the clinical case count implied, meaning many people with mild or asymptomatic infection were never captured in the denominator.

The true IFR (infection-fatality rate) was likely well below 30%. The 2026 outbreak's 14% confirmed CFR may partly reflect a similar phenomenon: improved case-finding (from the PHEIC mobilisation) is detecting milder cases that would not have been laboratory-confirmed in 2007, mathematically reducing the confirmed-CFR even if absolute deaths are higher.

Counter-parallel: The 2014-16 West Africa Zaire Ebola epidemic had a confirmed CFR that varied between 40% and 70% by country and time period, with the highest CFRs in Sierra Leone in mid-2014 when healthcare systems were overwhelmed and patients died at home before hospitalisation.

The mechanism driving high CFR was hospital saturation and home-death undercount, structurally identical to the 2026 Bundibugyo situation in Ituri, where treatment centres are operating at or near capacity and patients die before reaching care.

Consensus view: Anne Cori and Neil Ferguson at Imperial College London's MRC Centre for Global Infectious Disease Analysis have published CFR (case-fatality ratio) estimation methods for filovirus outbreaks that explicitly correct for right-censoring: patients who are still ill at the time of reporting are neither dead nor recovered, so a naive CFR divides deaths by all known cases and underestimates both the proportion who will die and the proportion who will recover.

In the 2026 Bundibugyo data, the 6.8:1 suspected-to-confirmed ratio compounds this by adding a second layer: many patients die before a laboratory swab can be taken, confirmed positive, and returned to count them. They appear only in the suspected total, which itself understates true cases because many individuals never reach a health facility at all.

Counter-view: The China CDC's modelling team and researchers at the Chinese Academy of Medical Sciences have, in past filovirus analyses, argued that the suspected-case category in WHO reporting carries such high specificity bias (only haemorrhagic-fever symptom presentations are entered) that a suspected Ebola case in an active outbreak zone has a prior probability above 70% of being a true case.

Under this framing, dividing deaths among all suspected cases rather than confirmed cases alone gives a more accurate CFR denominator, which for the 2026 Bundibugyo outbreak would yield a suspected-CFR of approximately 24% (241 deaths divided by 1,040 suspected cases). The correct figure almost certainly lies between the confirmed-case 14% floor and the suspected-case 24% ceiling.

Key tension: Which denominator policymakers use to communicate risk determines how urgently the outbreak is framed to the public and to donor governments: the difference between 14% and 24% CFR is not epidemiologically trivial and affects both risk communication and resource-mobilisation velocity.

Sources:World Health Organization

Mentions:World Health Organization →PHEIC →Uganda →Sierra Leone →China →Neil Ferguson →Anne Cori →Imperial College London →DON 600 →CDC →DR Congo →Bundibugyo ebolavirus →Ituri Province →

First Reported In

Update #5 · Ebola money arrives, the cure does not

World Health Organization· 2 Jun 2026

Read original →

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.

AI-assisted, human-edited under the editorial responsibility of Bannermedia Ltd. Reviewed by Ed Woodcock on 2 June 2026. Editorial standards.